Post on 19-Sep-2019
transcript
Biobanking for bimolecular research
Karine Sargsyan, MD, PhDManaging Director of Biobank
Medical University Graz
Definition
Structured collection of biological material and corresponding data
„hot spots“ for R&D
Tissue
BloodDNA
Biological samples
Data Bank
CellsProteins
OtherBodyfluids
Disease specific data
Personal dataunder Data savity and security
Collection
2Version 3.3
European research infrastructure
Innovative Medicine Initiative (2 Mrd. EUR)
ESFRI – Roadmap (35 Topics)
EATRIS
ELIXIR
INFRAFRONTIER ECRINBBMRI INSTRUCT
Version 3.3
Features of Research Infrastructures
Pan-EuropeanAgreement on long-termstrategyAdded value of cooperationAccessPower of scaleSustainability
Biomedical Research
Bioanalytical Chemistry Technology
Biotechnology
Information Systems/Computer Technology
Imaging Technologies
Animal testing
Drug Substance Manufacture
Survey Technology
Clinical Lab Technology
Clinical trial center
Bioanalytical Chemistry Technology
Clinical trial center
Survey Technology
Clinical Lab Technology
Information Systems/Computer Technology
Animal testing
Access to biological samples
Biobanks in Medical Research
NCI: Biological sampels are #1 roadblockOECD: Global Biological Resource Centre NetworkWHO/IARC: Standards for biological resource centresESF: Science Policy Briefing: Need for integrationEU/ESFRI: Research infrastructure for Biobanks and Biomolecular
Resources (BBMRI)
700,000 Cancer deaths
(North America; 2007)
Cancer Genome Project struggelswith sample shortage(Nature Medicine 2007)
ELSIFragmentation
FundingTechnical
Follow-up
BBMRI
Key Components of BBMRI
Fam. historyLab. param.
Treatm. outcomeLifestyle
PBMC
Serum
FFPEtissues
Frozentissues
Cells
AntibodiesAffinity binders
Recomb. proteins
Gene clone collections*
siRNA libraries*Cell lines*
Model organisms*
Sample storage
Human biological samplesand data
HealthyPopulation
Analysis tools
Patients
ApplicationBasic researchLife sciences
Targets forDrug discovery
Biomarkers forDrug development
New diagnostics
Personalized medicinePublic health
Infrastructure
Data storageBiocomputing
DNA
*: ESFRI BMS report but not funded
Ist-ZustandEuropäisches Umfeld
BBMRI-Partner und assozierte Institutionen
183 Associated organisations28 Countries
50 Participating institutions
Preparatory phase 27 monthsFunding 5 mio €
183 Associated organisations28 Countries
50 Participating institutions183 Associated organisations
28 Countries
50 Participating institutions
Preparatory phase 27 monthsFunding 5 mio €
The New Dimension in Life Sciences Research
networks networks networks
resources, technologiesservices
Individual research groups
pan-European research infrastructures
Access
CollaborationIntegration
Harmonization
CompetitionInnovation
Innovation circle
Benefits for Health Care Systems
Short termStandardization and international harmonization
Quality control and strategic planning
Avoidance of redundancies
Mid termBiological samples and data as a key resource for health care-related economies
Heath care as economic value generator
Long termBetter health care
Personalized medicine
Overview on 7109 Colon Cancer Cases
Overview on 7109 Colon Cancer Cases
Year Sex Age df Survival Staging T Staging N Staging M GradingExamination
96-99) SIGMAMANSCHETTE MIT EINEM OBERFLAECHLICH AUSGEDEHNT EXULCERIERTEN UND BEREITS FORTGESCHRITTEN INVASIVEN, MITTEL-DIFFERENZIERTEN, SAEMTLICHE DARMWANDSCHICHTEN DURCHSETZENDEN UND PERFORIERTEN ADENOKARZINOM MIT EINER KONSIKUTIVEN, ABSZEDIERENDEN UND AUCH PHLEGMONOESEN ENTZUENDUNG IM MITERFASSTEN PARACOLISCHEN FETT-UND BINDEGEWEBE OHNE JEDOCH NACHWEISBAREN LYMPHKNOTENMETASTASEN (RPT-3, PG-2, PN-0, R-0).27 TUMORFREIE HIST. VERIFIZIERBARE PARACOLISCHE
LYMPHKNOTEN SOWIE AUCH TUMORFREIER NETZANTEIL. TUMORFREIE APPENDIX MIT RESIDUEN NACH APPENDICITIS(FOKALE VERNARBUNG DER SUBMUKOSA). FOKALE FIBRINOES GRANULOZYTAERE PERICHOLEZYSTITIS (UEBERGREIFEN DER ENTZUENDUNGSINFILTRATE IM RAHMEN DER VERIFIZIERBAREN SIGMAPERFORATION DURCH DAS TUMORGEWEBE).
Possible Legal Structure of BBMRI (ERIC)
Distributed hub and spoke structure
National members
BiobanksBiomolecular res.Technology centers
Associated partnersHospitalsUniversitiesService providers …
Secretariat(statutory seat)
The Process
Evaluation of existing resources and solutionsIdentification of open issues
Concept for:Integration of existing resourcesIntegration of future resourcesProcess standardization, certificationAccess rulesIncentives and benefit sharingInternational exchange of samples and data
Operational concept Financial Plan Implementation Plan
MoU, Contracts
8 m
o3 m
o10 m
o3 m
o
Starting Points
OECD best practice guidelines for Biological Resource CentresOECD draft guidelines on Human Biobanks and Genetic Research Database
P3GInternational harmonization of biobanking
FP5-FP7, national programsExisting biobanks, resources and networks
The Adaptor Approach of BBMRI
Define criteriaWhich samples and data can becombined?
Develop toolsData exchange
Sample transport
Provide Access
BBMRI Prototype
To accomplish a great vision and complex process in a series of specific steps
Most advanced biobanks should start the construction of a prototype infrastructure already during preparatory phase on a voluntary basis
Requires support from national Funders and Ministries
Expected Impact of BBMRI
BBMRI should provide a pan-European framework to fosterexcellence in biomedical research
Better projects, faster, cheaper
Access to high quality resources, technologies, servicesPartner for academia and industry
SMEs: Strategic partner, customer
Pharma: Biomarker and drug development
Incubator for regional development
Synergies of BMS Research Infrastructures
EATRIS
ELIXIR
INFRAFRONTIER ECRIN
BBMRI
INSTRUCT
TargetId
TargetVal Hit Lead
LeadOptim Preclininc Phase I Phase II
Research Discovery Development
Phase III
e-Infrastructure
EMBRC EISBI EU OpenScreen
Euro Bio-Imaging
BSL4Laboratories
B i o b a n k i n g
B i o i n f o r m a t i c s
PP projects1st update of roadmapEmerging infrastructures
Opportunities for Regional Development
Biological resources are the essential raw material for futurehealt-related economiesBiomarkers are needed to increase the efficacy of drugdevelopment and value generationPart of European Research InfrastructureContact point for and integrator of eastern European resourcesFrom a resource provider to a resource integator and valuegenerator (biomarker center)
Cancer and Thrombosis Study
Hematologic Bank
MyoBANK Wien
AKH Biobank
Serumbank Gynecology
Hematology Biobank
Tissue Bank Gynecology
Prostata Biobank Innsbruck
Biobank der MUG
Vienna Drosophila RNAi CenteICNB
Bleeding Study
Vet Biobank
TissueBody fluids (Blood, sera, etc.) Derivate (DNA, Cell lines, etc.)
Surface is proportional to number of samples
Inventory of BiobanksBBMRI – AT
Inventory of BiobanksBBMRI –Europe
BB MUG
PBCCCM
NCT
TUM
LSH 3
TBGI
Banu BB
HP-CVDRF
NLCS
CRB Bichat
BBI
BMBACS
CNESPS
PBCCBF
ZONCO 3
MORGEN EPICMORGEN
BioPIC
LifeLines
CNIO
CEPH
BNA DN
Biobank 06
KompNet
Tissue, Blood, DNABlood, DNA
Surface is proportional to number of samples
25 Biobanks with the highest number of samples April 2009
Nr. PROJEKTTITELPROJEKTSUMM
E MUG
1 Genetische Marker zur Vorhersage des Verlaufes und Therapieansprechens Dickdarmkarzinomen 53.025,03
2 Bestimmung von c-Kit, PDGFRA, Beta Expression und Genmutation in Desmoid Tumoren 14.000,00
3 Gene-Silencing mittels siRNA in kleinzelligen Lungenkarzinomen 20.000,00
4 Immunhistochemische Marker bei extra-abdominellen aggressiven Fibromatosen 22.454,00
5 Regulation of basophils by chemokine-receptors 3.440,00
6 GOLD3 - Genomics Of Lipid Droplet Biology,Lipid droplet-associated proteins regulating lipid storage 164.414,00
7 GEN-AU III: GATiB 1.087.136,00
8 GENAU I 243.758,00
9 GATiB: Genome Austria Tissue Bank (SP3):Highly annotated tissue sample collection 385.820,10
10 GATiB:Genome Austria Tissue Bank (SP4):Specification documentation metabolic neoplastic iseases 506.730,00
11 GATiB: Genome Austria Tissue Bank (Koordinationsprojekt, SP1) 297.186,52
12 A gene expression data set for breast cancer 94.000,00
13 A comprehensive disease bank for functional genomics. 1.087.136,00
14 SFB LIPOTOX: Teilprojekt des Koordinationsprojekts (Pathophysiologischer Teil) 172.040,00
15 NANO-HEALTH: Nano-TOX 161.639,00
16 VIPEM, Visual Analytics for Personalized Medicine 131.991,00
17 SFB LIPOTOXICITY -Role of hepatobiliary bile acid transporters and nucler receptors in the control 446.880,00
18 Prostaglandin D2 als Mediator der Allergie 240.247,00
19 Geschlechtsspezifische Genexpresssion in Makrophagen 249.795,00
20 Die Rolle von c-Jun und JunB für die Lymphomenstehung 95.161,00
21 Kernrezeptoren als therapeutische Targets bei Cholestase 248.402,00
22 Molekulare Regulation hepatozellulärer Transportsysteme 176.877,00
23 Genexpressionsanalyse der Sarcoidose 173.172,00
24 Neue Mechanismen der selektiven Regulation von Basophilen 166.108,00
25 Pathogenese und Immunologie großzellig-anaplastischer Lymphome 242.080,00
26 SPIDIA - Standardisation and improvement of pre-analytical procedures for in vitro diagnostics 1.032.358,00
27 BBMRI: Biobanking and Biomolecular Resources Research Infrastructure 939.256,00
28 IMPACTS: ARCHIVE´S TISSUES: IMPROVING MOLECULAR MEDICINE RESEARCH AND 655.000,00
29 EPCRC_Biomarker als Nachweis für Schmerzwahrnehung und Therapieansprechen 221.256,00
30 Molecular-cytogenetic and gene expression study of adenocarcinomas possible precursor lesions 2.000,00
31 ESBIC-D European Systems Biology Initiative for combating Complex Diseases 41.200,00
32 PEROXISOMES: Integrated Project to decipher the biological function of peroxisomes 131.731,00
33 PONT: Parallel Optimization of New Technologies for Post-Genomics Drug Discovery 352.200,00
34 Vitamin D and new bone marker levels in breast cancer patients with and without bone metastases 66.000,00
35 Molecular alterations of intestinal bile acid homeostasis in inflammatory bowel disease 49.000,00
36 Type-I Diabetes Mellitus in Early Pregnancy: Effect on Placental Development 81.000,00
37 Rolle der Lipidmediatoren Prostaglandin D2, 5-oxo-ETE in Erkrankungen Respirationstraktes 75.000,00
38 Einfluss einer psychosozialen Intervention auf T und NK Zellfunktion von Patientinnen Mammakarzinom 68.000,00
39 Molekulare Effekte von Ursodeoxycholsäure auf die Expression hepatobiliärer ATP-binding Cassette 94.000,00
40 Plazenta, Fettsäuren und Diabetes 125.000,00
41 European Biobanking and Biomolecular Resources Infrastructure 30.390,00
42 Pathogenese endometrialen Stromasarkoms -SALDOW 1.764.574,00
43 Healthcare integrated Biobanking (RP7 Health 1. Stufe) 20.000,00
44 IMI European Medicines Research Training Network_NEBRIC 16.700,00
45 ARCSCREEN 5.275,00
46 High throughput biobanking technologies for tissues, cells and body fluids 12.000,00
47 Schwangerschaftsdiabetes 11.900,00
48 Vertragsverhandlungen zum EU-Projekt BBMRI 7.500,00
49 GENOPTIKUM 182.240,00
50 RZPD - CRIP 396.585,00
51 GENINCA 12.300,00
52 Evaluation of prognostic factors in patients with spinal metastases 3.000,00
53 GEN-View 153.100,00
54 Nano-HEALTH Verlengerung 530.000,00
55 Molekulargenetische Analysen von Knochen- und Weichteiltumoren 30.000,00
Gesamt 13.592.056,65
Version 3.3
Ausschließlich akademische Projekte im Biobank-Umfeld, ohne Industrie und klinische Studien
Projekte, die ohne Biobank nicht entstanden wären
Projects
24
Projects ( since 2005)
nur Anteil MUG, Gesamtprojektvolumen um vieles höher
Biobank
Projekt level
Infrastructur
General structure
25Version 3.3
Projekt-Ebene
Infrastruktur-Ebene
26
BIOBANKResearch
infrastructur
Academic and industrialCooperative research
Academicresearch
Industrialresearch
General structure
Version 3.3
Biobank
27Version 3.3
Planed SEE Projects
Harmonization of Clincal BiobanksSEEBI (South East European Biobanking Initiative)
Biobank-InfrastructureTEMPUS
WHO/ IACR - Trainingsprogramm
Proposed BBMRI Assets and Services
Handbook for operation of biobanksOpen source IT-solutionsStatistical powerhouseAdvice for QC and certificationGuidance to European ELSI landscapeTemplates for IC, MTA, CDAISO-certified analysis platformsBiomolecular resourcesTraining and educationModel for regional development
Mid-term Strategy
Biobank and biospecimen research is a specificstrength of MUGFrom a local resource provider to a global integratorBiobank research infrastructure as nucleus for ECIScientific focus on translational research
From models to humansFrom basic science to application
Biobank der MUGhttp://www.meduni-graz.at/1449biobank@meduni-graz.atTel: +43 316 385 72716Fax: +43 316 385 73009
Thanks for your attention